logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial | Conference Material / Slide Presentation | MSF Science Portal
Conference Material
|Slide Presentation

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA, Mohamed AA, Mohhamedelamin ESW, Bahar ME, Attalla HY, Siddig EE, Mahmoud NA, Musa AM, van de Sande WWJ, Scherrer B, Oyieko P, Egondi T, Onyango K, Hata K, Chu WY, Dorlo TPC, Nyaoke BA, Strub-Wourgaft N, Zijlstra EE
Download

Similar Content
Abstract
|Abstract
Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial
2024 May 16 • MSF Scientific Day International 2024
Loading...
Loading...
No abstract available

Countries

Sudan

Languages

English
DOI
10.57740/YDzkQTI
Published Date
16 May 2024
Conference
MSF Scientific Day International 2024
Linked Content
Conference Material
|Abstract
Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial
2024 May 16 • MSF Scientific Day International 2024